List of Altabax drug patents

Altabax is owned by Almirall.

Altabax contains Retapamulin.

Altabax has a total of 2 drug patents out of which 0 drug patents have expired.

Altabax was authorised for market use on 12 April, 2007.

Altabax is available in ointment;topical dosage forms.

Altabax can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.

The generics of Altabax are possible to be released after 14 February, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(1 year, 6 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in